ANEB OTC
Anebulo Pharmaceuticals, Inc.
1W: -1.5%
1M: +6.7%
3M: -13.0%
YTD: -71.7%
1Y: -86.7%
3Y: -90.2%
5Y: -95.4%
$0.32
+0.00 (+0.00%)
Weekly Expected Move ±12.6%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
-$9M
-11.0% ▼
Net Income
-$8M
-3.4% ▼
EPS (Diluted)
$-0.25
+21.9% ▲
EBITDA
-$8M
-4.0% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $2M | $3M | $6M | $4M | $4M |
| SG&A Expenses | $1M | $4M | $6M | $5M | $5M |
| Operating Expenses | $4M | $7M | $12M | $8M | $9M |
| Operating Income | -$4M | -$7M | -$12M | -$8M | -$9M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $12K | $0 | $0 | $151K | $382K |
| Income Before Tax | -$30M | -$7M | -$12M | -$8M | -$8M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$30M | -$7M | -$12M | -$8M | -$8M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-1.30 | $-0.29 | $-0.47 | $-0.32 | $-0.25 |
| EBITDA | -$30M | -$7M | -$12M | -$8M | -$8M |
| Shares Outstanding | 23M | 23M | 25M | 26M | 34M |